[
  {
    "id": "exampla",
    "name": "Exampla",
    "genericName": "examplamab",
    "companyId": "pfizer",
    "description": "A monoclonal antibody targeting inflammatory pathways. Exampla is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-12 (IL-12) and interleukin-23 (IL-23), two key cytokines involved in inflammatory and immune responses associated with autoimmune conditions.",
    "stage": "marketed",
    "therapeuticAreas": [
      "207RI0011X",
      "208D00000X"
    ],
    "indications": [
      "Rheumatoid Arthritis",
      "Psoriasis",
      "Psoriatic Arthritis"
    ],
    "moleculeType": "Monoclonal Antibody",
    "timeline": [
      {
        "date": "2015-03-10",
        "stage": "discovery",
        "description": "Lead antibody identified and characterized in preclinical studies."
      },
      {
        "date": "2016-05-20",
        "stage": "preclinical",
        "description": "IND-enabling studies completed with favorable safety profile."
      },
      {
        "date": "2016-11-15",
        "stage": "phase1",
        "description": "First-in-human clinical trial initiated in healthy volunteers."
      },
      {
        "date": "2017-06-28",
        "stage": "phase2",
        "description": "Phase 2 trials in rheumatoid arthritis and psoriasis patients showing promising efficacy."
      },
      {
        "date": "2018-02-12",
        "stage": "phase3",
        "description": "Global Phase 3 program initiated across multiple indications."
      },
      {
        "date": "2018-12-05",
        "stage": "approved",
        "description": "FDA approval for rheumatoid arthritis and psoriasis."
      },
      {
        "date": "2019-01-15",
        "stage": "market",
        "description": "Commercial launch in the United States."
      }
    ],
    "approvals": [
      {
        "region": "United States",
        "date": "2018-12-05",
        "indication": "Rheumatoid Arthritis",
        "agency": "FDA",
        "status": "approved",
        "details": "Approved for moderate to severe rheumatoid arthritis in adults who have had inadequate response to conventional therapy."
      },
      {
        "region": "United States",
        "date": "2018-12-05",
        "indication": "Plaque Psoriasis",
        "agency": "FDA",
        "status": "approved",
        "details": "Approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy."
      },
      {
        "region": "European Union",
        "date": "2019-03-18",
        "indication": "Rheumatoid Arthritis",
        "agency": "EMA",
        "status": "approved",
        "details": "Approved for moderate to severe active rheumatoid arthritis in adults with inadequate response to DMARDs."
      },
      {
        "region": "Japan",
        "date": "2019-06-22",
        "indication": "Plaque Psoriasis",
        "agency": "PMDA",
        "status": "approved",
        "details": "Approved for treatment of psoriasis vulgaris and psoriatic arthritis in patients who have not responded sufficiently to conventional therapies."
      },
      {
        "region": "United States",
        "date": "2022-04-11",
        "indication": "Psoriatic Arthritis",
        "agency": "FDA",
        "status": "approved",
        "details": "Approved for active psoriatic arthritis in adults."
      }
    ],
    "imageUrl": "/src/data/assets/products/exampla.svg",
    "website": "exampla.com",
    "patents": [
      {
        "number": "US9234567B2",
        "expiryDate": "2036-06-18",
        "description": "Composition of matter patent covering the monoclonal antibody formulation."
      },
      {
        "number": "US9876543B2",
        "expiryDate": "2035-11-30",
        "description": "Method of treatment patent for autoimmune conditions."
      },
      {
        "number": "EP3456789B1",
        "expiryDate": "2035-12-15",
        "description": "European patent covering manufacturing process."
      }
    ]
  },
  {
    "id": "cardiofix",
    "name": "CardioFix",
    "genericName": "amlodipivastatin",
    "companyId": "pfizer",
    "description": "A dual-action therapy for cardiovascular disease management. CardioFix combines a calcium channel blocker with a statin in a novel formulation, targeting both hypertension and hyperlipidemia simultaneously to reduce cardiovascular risk in patients with multiple risk factors.",
    "stage": "phase3",
    "therapeuticAreas": [
      "207RC0000X"
    ],
    "indications": [
      "Hypertension with Hyperlipidemia",
      "Atherosclerotic Cardiovascular Disease Prevention"
    ],
    "moleculeType": "Small Molecule",
    "timeline": [
      {
        "date": "2018-04-15",
        "stage": "discovery",
        "description": "Dual-action compound identified through computational drug design."
      },
      {
        "date": "2019-07-22",
        "stage": "preclinical",
        "description": "Preclinical studies demonstrated favorable pharmacokinetic profile and safety."
      },
      {
        "date": "2020-02-10",
        "stage": "phase1",
        "description": "Phase 1 trial initiated in healthy volunteers showing good tolerability."
      },
      {
        "date": "2021-05-18",
        "stage": "phase2",
        "description": "Phase 2 trials demonstrated significant reductions in both blood pressure and LDL-cholesterol."
      },
      {
        "date": "2022-11-08",
        "stage": "phase3",
        "description": "Global Phase 3 program initiated in patients with hypertension and hyperlipidemia."
      }
    ],
    "approvals": [
      {
        "region": "United States",
        "date": "2022-11-08",
        "indication": "Hypertension with Hyperlipidemia",
        "agency": "FDA",
        "status": "pending",
        "details": "Phase 3 clinical trials in progress for the treatment of patients with both hypertension and hyperlipidemia."
      },
      {
        "region": "European Union",
        "date": "2023-01-20",
        "indication": "Atherosclerotic Cardiovascular Disease Prevention",
        "agency": "EMA",
        "status": "pending",
        "details": "Clinical trials in progress for primary and secondary prevention of atherosclerotic cardiovascular disease."
      }
    ],
    "imageUrl": "/src/data/assets/products/cardiofix.svg",
    "website": "cardiofix-clinical.pfizer.com",
    "patents": [
      {
        "number": "US10123456B2",
        "expiryDate": "2039-04-15",
        "description": "Composition patent covering the dual-acting formulation."
      },
      {
        "number": "US10567890B2",
        "expiryDate": "2038-09-22",
        "description": "Method of treatment patent for cardiovascular risk reduction."
      }
    ]
  },
  {
    "id": "oncovax",
    "name": "OncoVax",
    "genericName": "tumovastumab",
    "companyId": "pfizer",
    "description": "Revolutionary personalized cancer vaccine that utilizes mRNA technology to target neoantigens specific to a patient's tumor. OncoVax is designed to stimulate the immune system to recognize and attack cancer cells that may remain after initial treatment, reducing the risk of recurrence in high-risk patients.",
    "stage": "phase2",
    "therapeuticAreas": [
      "207RO0000X"
    ],
    "indications": [
      "Melanoma",
      "Non-Small Cell Lung Cancer",
      "Colorectal Cancer"
    ],
    "moleculeType": "mRNA Vaccine",
    "timeline": [
      {
        "date": "2019-08-25",
        "stage": "discovery",
        "description": "Technology platform established for neoantigen identification and vaccine production."
      },
      {
        "date": "2020-11-12",
        "stage": "preclinical",
        "description": "Preclinical studies showed robust T-cell responses and tumor suppression in animal models."
      },
      {
        "date": "2021-09-30",
        "stage": "phase1",
        "description": "First-in-human study initiated in patients with resected melanoma."
      },
      {
        "date": "2023-01-15",
        "stage": "phase2",
        "description": "Phase 2 trials initiated in multiple tumor types after promising Phase 1 results."
      }
    ],
    "approvals": [
      {
        "region": "United States",
        "date": "2021-05-20",
        "indication": "Melanoma",
        "agency": "FDA",
        "status": "breakthrough",
        "details": "Granted Breakthrough Therapy designation for adjuvant treatment of high-risk melanoma."
      },
      {
        "region": "United States",
        "date": "2022-12-10",
        "indication": "Non-Small Cell Lung Cancer",
        "agency": "FDA",
        "status": "fast-track",
        "details": "Received Fast Track designation for adjuvant treatment of non-small cell lung cancer."
      }
    ],
    "imageUrl": "/src/data/assets/products/oncovax.svg",
    "website": "oncovax-clinical.pfizer.com",
    "patents": [
      {
        "number": "US11345678B2",
        "expiryDate": "2040-08-25",
        "description": "Platform technology patents covering personalized neoantigen identification."
      },
      {
        "number": "US11456789B2",
        "expiryDate": "2041-03-17",
        "description": "Patent covering mRNA delivery system specific for tumor neoantigens."
      }
    ]
  },
  {
    "id": "luxient",
    "name": "Luxient",
    "genericName": "fingomodex",
    "companyId": "novartis",
    "description": "Advanced targeted therapy for multiple sclerosis that modulates specific immune cell receptors to reduce inflammation and neurodegeneration in the central nervous system. Luxient represents a significant advance in MS treatment with improved selectivity and reduced side effects compared to earlier generation therapies.",
    "stage": "marketed",
    "therapeuticAreas": [
      "2084N0400X"
    ],
    "indications": [
      "Relapsing-Remitting Multiple Sclerosis",
      "Active Secondary Progressive Multiple Sclerosis"
    ],
    "moleculeType": "Small Molecule",
    "timeline": [
      {
        "date": "2012-10-18",
        "stage": "discovery",
        "description": "Novel compound identified through targeted screening program."
      },
      {
        "date": "2013-09-05",
        "stage": "preclinical",
        "description": "Preclinical studies demonstrated superior BBB penetration and CNS effects."
      },
      {
        "date": "2014-05-22",
        "stage": "phase1",
        "description": "Phase 1 trials showed favorable safety profile and target engagement."
      },
      {
        "date": "2015-03-12",
        "stage": "phase2",
        "description": "Phase 2 trials demonstrated significant reduction in gadolinium-enhancing lesions."
      },
      {
        "date": "2015-11-30",
        "stage": "phase3",
        "description": "Global Phase 3 program initiated in relapsing MS patients."
      },
      {
        "date": "2016-03-22",
        "stage": "approved",
        "description": "FDA approval for relapsing forms of MS."
      },
      {
        "date": "2016-05-01",
        "stage": "market",
        "description": "Commercial launch in the United States."
      },
      {
        "date": "2020-08-15",
        "stage": "market",
        "description": "Label expansion to include active secondary progressive MS."
      }
    ],
    "approvals": [
      {
        "region": "United States",
        "date": "2016-03-22",
        "indication": "Relapsing-Remitting Multiple Sclerosis",
        "agency": "FDA",
        "status": "approved",
        "details": "Approved for treatment of patients with relapsing forms of multiple sclerosis."
      },
      {
        "region": "European Union",
        "date": "2016-07-18",
        "indication": "Relapsing-Remitting Multiple Sclerosis",
        "agency": "EMA",
        "status": "approved",
        "details": "Approved for treatment of adult patients with highly active relapsing-remitting multiple sclerosis."
      },
      {
        "region": "United States",
        "date": "2020-08-15",
        "indication": "Secondary Progressive Multiple Sclerosis",
        "agency": "FDA",
        "status": "approved",
        "details": "Approved for active secondary progressive multiple sclerosis with relapses."
      }
    ],
    "imageUrl": "/src/data/assets/products/luxient.svg",
    "website": "luxient.com",
    "patents": [
      {
        "number": "US8765432B2",
        "expiryDate": "2033-10-18",
        "description": "Composition of matter patent covering the active pharmaceutical ingredient."
      },
      {
        "number": "US9087654B2",
        "expiryDate": "2034-06-30",
        "description": "Method of treatment patent for neurological disorders."
      },
      {
        "number": "EP2654321B1",
        "expiryDate": "2033-11-25",
        "description": "European patent covering pharmaceutical formulation."
      }
    ]
  },
  {
    "id": "respiclear",
    "name": "RespiClear",
    "genericName": "fluticasalumab",
    "companyId": "astrazeneca",
    "description": "Next-generation inhaled therapy for severe asthma and COPD that combines a long-acting muscarinic antagonist, a long-acting beta-agonist, and an inhaled corticosteroid in a single innovative inhalation device. RespiClear provides enhanced bronchodilation and anti-inflammatory effects with once-daily dosing.",
    "stage": "marketed",
    "therapeuticAreas": [
      "207RP0002X"
    ],
    "indications": [
      "Severe Asthma",
      "Chronic Obstructive Pulmonary Disease"
    ],
    "moleculeType": "Biologic-Small Molecule Combination",
    "timeline": [
      {
        "date": "2015-06-30",
        "stage": "discovery",
        "description": "Triple combination concept established and formulation work initiated."
      },
      {
        "date": "2016-08-15",
        "stage": "preclinical",
        "description": "Preclinical testing demonstrated enhanced efficacy compared to dual therapies."
      },
      {
        "date": "2017-03-22",
        "stage": "phase1",
        "description": "Phase 1 trials in healthy volunteers demonstrated good safety and tolerance."
      },
      {
        "date": "2017-11-08",
        "stage": "phase2",
        "description": "Phase 2 studies showed significant improvements in lung function."
      },
      {
        "date": "2018-05-17",
        "stage": "phase3",
        "description": "Global Phase 3 program initiated in asthma and COPD patients."
      },
      {
        "date": "2019-11-10",
        "stage": "approved",
        "description": "FDA approval for severe asthma and COPD."
      },
      {
        "date": "2020-01-15",
        "stage": "market",
        "description": "Commercial launch in the United States."
      }
    ],
    "approvals": [
      {
        "region": "United States",
        "date": "2019-11-10",
        "indication": "Severe Asthma",
        "agency": "FDA",
        "status": "approved",
        "details": "Approved for maintenance treatment of patients with severe asthma."
      },
      {
        "region": "United States",
        "date": "2019-11-10",
        "indication": "COPD",
        "agency": "FDA",
        "status": "approved",
        "details": "Approved for maintenance treatment of patients with COPD."
      },
      {
        "region": "European Union",
        "date": "2020-02-28",
        "indication": "Severe Asthma",
        "agency": "EMA",
        "status": "approved",
        "details": "Approved for maintenance treatment of severe asthma in adult patients."
      },
      {
        "region": "European Union",
        "date": "2020-02-28",
        "indication": "COPD",
        "agency": "EMA",
        "status": "approved",
        "details": "Approved for symptomatic treatment of adults with COPD with FEV1 < 70% predicted."
      }
    ],
    "imageUrl": "/src/data/assets/products/respiclear.svg",
    "website": "respiclear.com",
    "patents": [
      {
        "number": "US9876543B2",
        "expiryDate": "2036-06-30",
        "description": "Composition patent covering the triple combination."
      },
      {
        "number": "US10234567B2",
        "expiryDate": "2035-12-15",
        "description": "Patent covering the novel inhalation device."
      },
      {
        "number": "EP3012345B1",
        "expiryDate": "2036-08-22",
        "description": "European patent covering formulation stability."
      }
    ]
  }
]